BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

≡

PROGRAM

2024 Innovation Forum Agenda

​​

2024 Innovation Forum Agenda

Date July 24-26, 2024

Venue July 24 Room 701AB & 701C, 7F, TaiNEX2
July 25-26 Room 401, 4F, TaiNEX1

Day 1 - Wednesday, July 24
Day 2 - Thursday, July 25
Day 3 - Friday, July 26

09:00 – 10:15

Session 1 (Plenary) – Global Biotech Development

09:00 – 09:05

Conference Opening

Welcoming Remarks

09:05 – 09:15

Session Chair

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

Greetings from BIO

Hilary Stiss, Executive Director, International Council of Biotech Associations

09:15– 09:45

Industry Leader Lecture
Pioneering company creation model and opportunities in APAC

09:45 – 10:15

Tang Prize Lecture

Exploration of Biological Diversity

Feng Zhang, Tang Prize Laureate; James and Patricia Poitras Professor in Neuroscience, Professor of Brain Cognitive Sciences and Biological Engineering, Massachusetts Institute of Technology

10:20 – 12:05

Session 2 (Plenary) – Global Biotech Development

10:20 – 10:40

Global Biotech Top Trends --- From a US Silicon Valley VC Prospective

Anis Uzzaman, Founder & CEO, Pegasus Tech Ventures, Inc.

10:40 – 11:00

Bioconvergence: how the intersection of biology and technology can advance human health

Paru Deshpande, Vice President R&D, Health Technologies, Imec vzw

11:00 – 11:20

Emerging Trends in the Global Health Industry

Zubin J. Daruwalla, M. D., PwC Singapore and Asia Pacific Health Industries Leader, PwC Singapore

11:20 – 11:40

Global trends and Future Opportunities in Pharma

Brian Mi, President, Asia Pacific IQVIA​

11:40 – 12:00

Evidence Based Cell and Gene Therapies: Global development for local benefit

Miguel Forte, CEO & Co-Founder, Kiji Therapeutics; President, International Society for Cell & Gene Therapy (ISCT)

12:00 – 12:05

Closing Remarks

Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization

12:30 – 14:00

Session 3  (Plenary) – Through International Alignment for a Healthier Taiwan

12:30 – 12:40

Opening Remarks

12:40 – 12:55

Empowering Taiwanese Biomedical Startups through International Collaboration

Lily Wong, Partner, PwC Taiwan

12:55 – 13:10

Establish an Interdisciplinary Collaboration Platform for Biomedical Innovations in Taiwan

Eric Y. Chuang, Vice President,  General Director, Biomedical Technology and Device Research Laboratories, ITRI

13:10 – 13:25

Toward Enhancing Japan's Drug Discovery Capabilities

​Toshihiko Takeda, Special Advisor, National Healthcare Policy Secretariat, Cabinet Secretariat, Government of Japan.

13:25 – 13:55

Panel Discussion

Moderator:


Panelists:

13:55 – 14:00

Closing Remarks

Hide Katsuma, President of IRPMA, General Manager of Eli Lilly, Eli Lilly and Company (Taiwan), Inc.

14:10 – 15:40

Session 4 – ADC Drug Development and Manufacturing Trends Challenges and Solutions

14:10 – 14:15

Opening Remarks

Lee-Cheng Liu, Founder, Chairman & President, EirGenix, Inc.

14:15 – 14:35

Challenges and Opportunities of ADC Drug Development: Regulatory Considerations

Heidi Wang, CEO, OBI Pharma

14:35 – 14:55

Strategies for Widening the Therapeutic Window

Gur Roshwalb, Partner, aMoon Fund

14:55 – 15:15

Nab2-ADC: Revolutionizing Antibody-Drug Conjugates with Enhanced Targeting and Safety

Gui-Dong Zhu, CEO, SparX Biopharmaceutical Corp.
15:15– 15:40

Panel Discussion

Moderator:
Lee-Cheng Liu, Founder, Chairman & President, EirGenix, Inc.

Panelists:

16:00 – 17:30

Session 5 – Frontier of Gene and Cell Therapies

16:00 – 16:03

Opening Remarks

Chien-Tsun Kuan, President / CEO and Co-Founder, ARCE Therapeutics, Inc.

16:03 – 16:20

Overview of Landscape for Cell and Gene Therapies; An update

John Tsai,Executive Partner, Syncona Ltd.

16:20 – 16:40

Driving the next generation of innovative and affordable cell therapies across indications

Alex Shih-Min Huang,VP & Head of Cell Therapy, BeiGene, BeiGene (Taiwan) Limited

16:40 – 16:55

Early Engagement Strategies to Cell and Gene Therapies Up for Success

Chia-Hua Maggie Ho, COO, Amarex Taiwan, LLC. 

16:55 – 17:10

Integration of MSC Value Chain with Enabling Manufacturing Platforms

David Chang, Ph.D., CEO, Taiwan Bio-Manufacturing Corporation (TBMC)

17:10 – 17:25

Investors viewpoint on cell and gene therapy

Gur Roshwalb, Partner, aMoon Fund

17:25 – 17:30

Closing Remarks